ReviewCurrent opinion in hematology2018
Hemolysis and immune regulation.
Review in Current opinion in hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 56 citations in OpenAlex.
- Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study.American journal of hematology · 2020Trial
- Targeting erythroid cell-derived asparagine inhibits alloimmunization in sickle cell disease.Blood advances · 2026Article
- Optimization of Production Conditions for Extracellular Vesicles from Lacticaseibacillus Paracasei LH23 Using Response Surface Methodology: Enhancement of Yield and Exploration of Stability, Safety, and Anti-inflammatory Capacity.Probiotics and antimicrobial proteins · 2026Article
- Immunopathogenesis of Sickle Cell Disease: Mechanisms of Immune Dysregulation and Clinical Consequences, a Narrative Review.Journal of blood medicine · 2026Review
- One trigger, two fates: hemolysate shapes neutrophil extracellular traps (NETs) formation in a context-dependent manner.Frontiers in immunology · 2026Article
- Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.Blood advances · 2025Review
- Heme in Bacterial Pathogenesis and as an Antimicrobial Target.Chemical reviews · 2025Review
- Dual-Functional Amine-Modified Aluminum-Doped MCM-41 Nanoparticles for Concurrent Zoledronic Acid Adsorption and Geranylgeraniol Delivery for Prevention of Medication-Related Osteonecrosis of the Jaw.ACS materials Au · 2025Article
- Nutritional, Antibacterial and Thrombolytic Prospects of FreshwaterFood science & nutrition · 2025Article
- Alterations of T Cell Subsets Associated with Sickle Cell Trait.Blood and genomics discovery · 2025Article
- Harnessing the potential of red blood cells in immunotherapy.Human immunology · 2024Review
- The Possible Effects of Galectin-3 on Mechanisms of Renal and Hepatocellular Injury Induced by Intravascular Hemolysis.International journal of molecular sciences · 2024Review
- Passenger lymphocyte syndrome following minor ABO-mismatched liver transplantation.BMJ case reports · 2024Article
- Cell-Free Hemoglobin in the Pathophysiology of Trauma: A Scoping Review.Critical care explorations · 2024Article
- Immunoregulation role of the erythroid cells.Frontiers in immunology · 2024Review
- Heme (dys)homeostasis and liver disease.Frontiers in physiology · 2024Review
- Evaluation of Lymphocyte Subgroups in Children with Glucose-6- Phosphate Dehydrogenase Deficiency.Turkish archives of pediatrics · 2023Article
- Monoclonal Gammopathy of Thrombotic Significance.Cancers · 2023Review
- Gut microbial change after administration ofFrontiers in endocrinology · 2023Article
- Liver Disease and Sickle Cell Disease: Auto-Immune Hepatitis more than a Coincidence; A Systematic Review of the Literature.Mediterranean journal of hematology and infectious diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewHemolytic anemias caused by premature destruction of red blood cells occur in many disorders including hemoglobinopathies, autoimmune conditions, during infection or following reaction to drugs or transfusions. Recent studies which will be reviewed here have uncovered several novel mechanisms by which hemolysis can alter immunological functions and increase the risk of severe complications in hemolytic disorders. RECENT
findingsPlasma-free heme can induce the formation of neutrophil extracellular traps (NETs) through reactive oxygen species signaling. Although NETs protect the host against infections, in patients with sickle disease, they are associated with vaso-occlusive crises. Heme may increase host susceptibility to infections by inducing heme oxygenase 1 (HO-1) in immature neutrophils, thereby inhibiting oxidative burst required for clearance of engulfed bacteria. In addition, heme impairs macrophage phagocytosis and microbial clearance through inhibition of cytoskeletal remodeling. Hemolysis can also favor anti-inflammatory immune cell polarization by inhibiting dendritic cell maturation necessary for effector T-cell responses, inducing differentiation of monocytes into red pulp macrophages, important for iron recycling from senescent erythrocytes, and driving regulatory T-cell expansion through modulation of HO-1 expression in nonclassical monocytes. SUMMARY: Hemolysis breakdown products show remarkable effects on the regulation of immune cell differentiation and function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.